CTIS2024-511317-38-00进行中（未招募）1 期
Clinical Utility of Liquid Biopsy as a tool to assess the evolution of brigatinib treated patients with non-small cell lung cancer with EML4-ALK translocation: an exploratory study (CUBIK)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male or female, aged equal or greater =18 years old, Normal QT interval (QT) on screening ECG evaluation, defined as QT interval corrected (Fridericia) (QTcF) of = 450 milliseconds (msec) in males of = 470 msec in females, Adequate hematologic and organ function, All patients are notified of the investigational nature of this study and signed a written informed consent in accordance with institutional and national guidelines, including the Declaration of Helsinki prior to any trial-related intervention., Willingness and ability to comply with scheduled visits and study procedures, For female patients of childbearing potential, a negative pregnancy test must have been documented prior to enrollment (within 14 days prior to enrollment), ECOG performance status of 0-2, Histologically or cytologically confirmed, Stage IIIB or IV NSCLC, Patients who have documented locally ALK rearrangement, No prior treatment for Stage IIIB or IV non-squamous NSCLC., Having a life expectancy = 3 months, Patients who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemo-radiotherapy with curative intent for non-metastatic disease must have experienced a treatment-free interval of at least 6 months from enrollment since the last chemotherapy, radiotherapy, or chemo-radiotherapy., Untreated or treated CNS metastases allowed, as long as asymptomatic and neurologically stable, Patients with at least 1 measurable lesion, as defined by RECIST v1.1
排除标准
- •Patients with a known sensitizing mutation in the epidermal growth factor receptor (EGFR) gene, STK-1 Ligand alteration, MDM2 amplification or ROS1 translocations., Have uncontrolled hypertension, Positive test for HIV. A and patients with active hepatitis B or active tuberculosis, Severe infections within 2 weeks prior to be included in the study, Have significant, uncontrolled or active cardiovascular disease, Patients with illnesses or conditions that interfere with their capacity to understand follow and/or comply with study procedures, Patients that received any prior TKI, including ALK-targeted TKIs or any systemic anticancer therapy for locally advanced or metastasic disease, Patients that have received chemotherapy or radiation within 14 days of first dose of study drug., Symptomatic CNS metastases (parenchymal or leptomeningeal) that are neurologically unstable or required an increasing dose of corticosteroids within 7 days prior to first dose of study drug, Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Patients with leptomeningeal disease and without cord compression is allowed., Malignancies other than NSCLC within 3 years prior to enrollment, Women who are pregnant, lactating, or intending to become pregnant during the study, Patients that received monoclonal antibodies or had major surgery within 30 days of the first dose of brigatinib, History of idiopathic pulmonary fibrosis, pulmonary interstitial disease, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
研究者
相似试验
进行中（未招募）
1 期
tility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutationsALK+ non-small cell lung cancerMedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2019-002369-36-ESFundación GECP30
已完成
不适用
Investigation on the usefulness of liquid biopsy for tumor-derived circulating DNA in patients with EGFR-mutant NSCLC during and after treatment with EGFR-TKIson-small cell Lung CancerJPRN-UMIN000023248PHRF122
招募中
不适用
Exploratory research of liquid biopsy for patients with cancercancerJPRN-UMIN000033269Cancer Precision Medicine Center Cancer Institute,800
进行中（未招募）
2 期
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ PatientsNSCLC Stage IIIBNSCLC Stage IVLung CancerNSCLCNCT04223596Fundación GECP33
尚未招募
不适用
Clinical efficacy of Liquid biopsy for acquired resistance to afatinib in EGFR positive NSCLCEGFR mutation positive NSCLCJPRN-UMIN000025112Aichi cancer center100